Kwang Dong Pharmaceutical Co., Ltd.
KRX:009290.KS
5570 (KRW) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,514,454.148 | 1,431,545.255 | 1,338,181.554 | 1,243,769.596 | 1,238,254.696 | 1,180,219.947 | 1,141,565.921 | 1,056,428.809 | 955,453.632 | 522,274.345 | 468,384.62 | 332,641.298 | 313,986.323 | 289,434.907 | 276,585.2 | 276,172.8 | 250,523.205 |
| Cost of Revenue
| 1,219,335.374 | 1,149,497.529 | 1,063,928.866 | 986,061.06 | 979,586.865 | 938,626.057 | 894,456.613 | 808,717.55 | 722,809.973 | 328,239.818 | 297,951.611 | 197,027.031 | 177,279.111 | 163,000.185 | 156,612.004 | 155,617.207 | 140,364.17 |
| Gross Profit
| 295,118.774 | 282,047.727 | 274,252.688 | 257,708.536 | 258,667.831 | 241,593.889 | 247,109.308 | 247,711.26 | 232,643.658 | 194,034.527 | 170,433.009 | 135,614.268 | 136,707.212 | 126,434.722 | 119,973.196 | 120,555.593 | 110,159.035 |
| Gross Profit Ratio
| 0.195 | 0.197 | 0.205 | 0.207 | 0.209 | 0.205 | 0.216 | 0.234 | 0.243 | 0.372 | 0.364 | 0.408 | 0.435 | 0.437 | 0.434 | 0.437 | 0.44 |
| Reseach & Development Expenses
| 15,274.81 | 9,678.204 | 8,321.983 | 5,956.996 | 5,338.9 | 4,178.917 | 1,513.248 | 5,025 | 456.555 | 0 | 0 | 0 | 0 | 0 | 0 | 200 | 90 |
| General & Administrative Expenses
| 15,170.543 | 14,783.616 | 13,127.275 | 11,453.108 | 14,552.206 | 13,861.342 | 14,614.719 | 14,985.13 | 13,147.015 | 11,765.49 | 10,435.363 | 9,628.451 | 9,506.278 | 11,659.126 | 11,305.478 | 12,334.224 | 9,328.272 |
| Selling & Marketing Expenses
| 133,099.66 | 126,130.895 | 124,112.118 | 112,797.187 | 114,285.176 | 107,508.854 | 118,455.799 | 115,729.724 | 97,744.805 | 79,523.766 | 65,551.237 | 47,373.827 | 47,186.977 | 40,737.24 | 41,519.366 | 42,425.867 | 35,912.156 |
| SG&A
| 233,848.333 | 140,914.511 | 137,239.393 | 124,250.295 | 128,837.382 | 121,370.196 | 133,070.518 | 130,714.854 | 110,891.82 | 91,289.256 | 75,986.6 | 57,002.278 | 56,693.255 | 52,396.366 | 52,824.844 | 54,760.091 | 45,240.428 |
| Other Expenses
| 0 | 93,210.57 | 83,755.629 | 80,910.531 | 82,688.311 | 748.763 | -820.386 | -2,794.711 | -1,030.227 | -2,241.281 | -1,283.603 | 771.299 | 951.774 | -744.048 | -2,106.195 | 1,566.861 | -348.373 |
| Operating Expenses
| 249,123.143 | 243,803.285 | 229,317.005 | 211,117.822 | 216,864.593 | 207,648.986 | 211,371.858 | 203,322.313 | 181,777.196 | 143,575.278 | 126,043.445 | 99,273.836 | 96,561.974 | 88,135.18 | 87,001.208 | 90,669.203 | 79,599.425 |
| Operating Income
| 48,767.648 | 38,244.442 | 44,935.684 | 46,590.713 | 41,803.238 | 33,944.903 | 35,737.45 | 44,388.946 | 50,866.462 | 50,459.249 | 44,389.563 | 36,340.432 | 38,614.544 | 38,299.543 | 32,971.988 | 29,886.393 | 30,559.61 |
| Operating Income Ratio
| 0.032 | 0.027 | 0.034 | 0.037 | 0.034 | 0.029 | 0.031 | 0.042 | 0.053 | 0.097 | 0.095 | 0.109 | 0.123 | 0.132 | 0.119 | 0.108 | 0.122 |
| Total Other Income Expenses Net
| 251.688 | -8,379.908 | -10,606.999 | 8,488.569 | -5,033.643 | -2,549.009 | -2,386.635 | -4,196.399 | -1,081.863 | -2,107.218 | -4,520.468 | 1,179.19 | 2,053.574 | -824.151 | -246.315 | 2,805.054 | 1,030.79 |
| Income Before Tax
| 49,019.337 | 36,290.716 | 34,328.685 | 62,950.97 | 36,769.594 | 31,395.894 | 33,350.815 | 40,192.547 | 49,717.778 | 47,350.402 | 39,826.729 | 37,519.622 | 40,668.118 | 37,475.392 | 32,725.673 | 32,691.447 | 31,590.4 |
| Income Before Tax Ratio
| 0.032 | 0.025 | 0.026 | 0.051 | 0.03 | 0.027 | 0.029 | 0.038 | 0.052 | 0.091 | 0.085 | 0.113 | 0.13 | 0.129 | 0.118 | 0.118 | 0.126 |
| Income Tax Expense
| 9,647.574 | 9,590.017 | 8,787.94 | 17,349.003 | 14,113.793 | 9,421.474 | 10,267.728 | 12,292.952 | 13,634.615 | 12,287.145 | 17,828.145 | 9,758.059 | 10,774.272 | 12,261.682 | 9,539.847 | 11,284.639 | 7,427.92 |
| Net Income
| 36,965.562 | 24,173.931 | 24,019.071 | 45,369.773 | 23,058.316 | 22,345.019 | 23,196.13 | 28,062.801 | 35,015.308 | 35,043.972 | 22,037.369 | 27,823.696 | 29,923.095 | 25,213.71 | 23,185.826 | 21,406.809 | 24,162.48 |
| Net Income Ratio
| 0.024 | 0.017 | 0.018 | 0.036 | 0.019 | 0.019 | 0.02 | 0.027 | 0.037 | 0.067 | 0.047 | 0.084 | 0.095 | 0.087 | 0.084 | 0.078 | 0.096 |
| EPS
| 913.39 | 588.45 | 584.68 | 1,119.49 | 581.72 | 551 | 572 | 692 | 868 | 869 | 538 | 668 | 683 | 552 | 497 | 447 | 489 |
| EPS Diluted
| 913.39 | 588.45 | 584.33 | 1,119.49 | 581.72 | 551 | 572 | 692 | 868 | 869 | 538 | 668 | 683 | 552 | 497 | 447 | 489 |
| EBITDA
| 67,440.264 | 54,512.74 | 51,023.396 | 85,190.181 | 58,724.07 | 51,591.314 | 51,099.369 | 57,305.947 | 62,390.431 | 58,057.636 | 51,979.097 | 46,282.67 | 47,922.616 | 44,902.762 | 41,934.37 | 42,519.733 | 41,749.371 |
| EBITDA Ratio
| 0.045 | 0.04 | 0.048 | 0.057 | 0.053 | 0.046 | 0.045 | 0.055 | 0.066 | 0.111 | 0.112 | 0.14 | 0.158 | 0.158 | 0.149 | 0.16 | 0.166 |